Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/2003
10/22/2003EP1150661B1 Topical sprays comprising a film forming composition
10/22/2003EP1140105B1 Controlled release galantamine composition
10/22/2003EP1077677B1 Process for the manufacture of a biologically active composition
10/22/2003EP1041984B1 Pharmaceutical composition for oral administration
10/22/2003EP0975334B1 Biodegradable microparticles for the sustained delivery of therapeutic drugs
10/22/2003EP0948321B1 Preparation in form of a matrix material-auxiliary agent compound containing optionally an active substance
10/22/2003EP0948319B1 Encapsulated cells producing antibodies
10/22/2003EP0929293B1 Liposomes containing a cisplatin compound
10/22/2003EP0904051B1 Cosmetic or pharmaceutical preparations with a reduced feeling of stickiness
10/22/2003EP0877600B1 Preservative systems for pharmaceutical compositions containing cyclodextrins
10/22/2003EP0773781B1 Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
10/22/2003CN1451043A Dual specificity antibodies and methods of making and using
10/22/2003CN1450923A Method and compositions for administering taxanes orally to human patients
10/22/2003CN1450915A Matrix metalloproteinase inhibitors as targeting components in diagnostic agents
10/22/2003CN1450914A Preparation of aqueous clear solution dosage forms with bile acids
10/22/2003CN1450908A Neurotoxic oligomers
10/22/2003CN1450905A Method for improving the cell protection
10/22/2003CN1450896A Use of indole derivatives for intracular pressure for reducing
10/22/2003CN1450895A Pharmaceutical compositions of estrogenic agents
10/22/2003CN1450891A Formulation based on heparin, glycosaminogl ycan or heparinoid, use of the formulation and the formulation base
10/22/2003CN1450890A Novel compositions of minoxidil
10/22/2003CN1450882A Transdermal administration of huperzine
10/22/2003CN1450065A Haptens, immunogens, and conjugates for 2-oxo-3-hydroxy LSD
10/22/2003CN1449862A Multiple emulsions
10/22/2003CN1449834A Use of 2-hydroxypropyl beta-cyclodextrin in preparing sodium new houttuy fonate injection
10/22/2003CN1449825A Method for inactivating Bordetella bronchiseptica culture, bacteria composition prepared by same and vaccine having same and use thereof
10/22/2003CN1449764A Roxithromycin slow-released pharmaceutics and preparation process thereof
10/22/2003CN1449760A Composition of danazol semisolid skeleton preparation
10/22/2003CN1449753A Chlorogenic acid and isochlorogenic acid composition and medical use thereof
10/22/2003CN1449752A Cantharidin total anhydride pharmaceutics for treating and preventing SARS and preparation thereof
10/22/2003CN1449750A Gabapentin slow -released composition
10/22/2003CN1449747A Built natural vegetable gum and use in preparation of soft capsule
10/22/2003CN1449746A Soft capsule containing trace element
10/22/2003CN1449745A Coated solid hyponotic
10/22/2003CN1449744A Antifungal agent and preparation and use method
10/22/2003CN1449742A Insoluble medicine transdemal absorption preparation and process for preparing same
10/22/2003CN1125174C Recombinant phages
10/22/2003CN1125145C Stable aqueous dispersions and stable water-dispersible dry powders of xanthophylls and production and use of the same
10/22/2003CN1125097C Precursor of polyglycol carried taxusol or polyene taxusol
10/22/2003CN1125040C Therapeutic compound-fatty acid conjugates
10/22/2003CN1124988C Activated medical water and its preparing process and usage
10/22/2003CN1124877C Solid and semi-solid hydrocarbon gels and use thereof
10/22/2003CN1124858C Medicine for treating blood vessel embolism and its preparing process
10/22/2003CN1124844C Stable freeze-dried pharmaceutical formulation
10/22/2003CN1124842C Sustained release eyedrops
10/21/2003US6635786 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use
10/21/2003US6635680 Controlled release pellet formulation
10/21/2003US6635676 Non-toxic antimicrobial compositions and methods of use
10/21/2003US6635674 Oleic acid and/or oleyl alcohol; increasing skin absorption
10/21/2003US6635628 Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
10/21/2003US6635618 Glycopeptide phosphonate derivatives
10/21/2003US6635476 Complex of recombinant virus-chelating peptide covalently linked to ligand through a transition metal ion; kinetically stable; use in delivering a therapeutic or diagnostic agent to a cell
10/21/2003US6635467 Monascus purpureus mutant and its use in preparing yellow pigment
10/21/2003US6635462 Mutated form of arginine deiminase
10/21/2003US6635456 Generation of preferential phosphatides; obtain phosphatide, incubate with phosphatidyl glycerol, incubate phospholipase, recover phosphatide
10/21/2003US6635417 Complex formation between DSDNA and oligomer of cyclic heterocycles
10/21/2003US6635288 Pulverizing in solvent; therapy for liver disorders
10/21/2003US6635283 Biocompatible particles having therapeutic, prophylactic or diagnostic agent, and of given mass mean diameter and aerodynamic diameter; at least 46% of the mass of particles are deposited after the first bifurcation of the lungs
10/21/2003US6635282 Gellan gum tablet film coating
10/21/2003US6635279 Active ingredient-containing floating forms comprising polyvinyl acetate and polyvinylpyrrolidone, their use and production
10/21/2003US6635278 Nucleotide analog 9-(2-((bis((pivaloyloxy)methyl)phosphono)methoxy)ethyl) adenine and an alkaline excipient with or without L-carnitine-L- tartrate. The compositions are more stable
10/21/2003US6635274 Solution-based transdermal drug delivery system
10/21/2003US6635270 NMDA receptor agonist pharmaceutical compositions
10/21/2003US6635254 Comprises biodegradable and biocompatible polymer carrying cationic charge on suface; sustained release/drug delivery
10/21/2003US6635253 Composition for enhancing immunological effects
10/21/2003US6635248 Isolated polypeptide consisting of single chain of amino acids comprising one or more penetrating fragments from one or more penetrating antibodies, which penetrates into cell
10/21/2003US6635243 Drug including genetically engineered alpha, beta or gamma interferon, biocompatible polymer selected from group consisting of polyvinylpyrrolidone and polyethylene oxide, and biocompatible antioxidant, and having specified viscosity
10/21/2003US6635045 Silver/silver chloride; reservoir comprising aqueous sodium chloride dispersed therein; corrosion resistance; transdermal
10/21/2003US6634576 At least one composition of media bodies provides fragments of milling media bodies that are retained with the milled solid substrate particles in the form of a synergetic commixture produced in the milling process.
10/21/2003CA2225352C Vegetable derived petroleum jelly replacement
10/21/2003CA2141964C Pharmaceutical agents containing diphosphonic acids and salts thereof
10/21/2003CA2115049C Dna sequences encoding gelonin polypeptide
10/21/2003CA2037884C Stabilized gonadotropin containing preparations
10/16/2003WO2003085121A2 Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer
10/16/2003WO2003085093A2 Antibodies that specifically bind to gmad
10/16/2003WO2003085031A1 Swellable, easily cross-linked, essentially linear polymers, and the use of the same in solid phase synthesis
10/16/2003WO2003085019A1 Cross-linked polyurethanes consisting of polytetrahydrofuran
10/16/2003WO2003084926A2 Polymeric acyl derivatives of indoles
10/16/2003WO2003084580A1 Hydrogel adhesives for use on hair or fiber-populated surfaces
10/16/2003WO2003084574A1 Multivalent constructs for therapeutic and diagnostic applications
10/16/2003WO2003084573A1 Polyfunctional biocompatible hydrogel and method for the production thereof
10/16/2003WO2003084564A1 Insulin administration apparatus
10/16/2003WO2003084553A1 Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis
10/16/2003WO2003084539A2 New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
10/16/2003WO2003084536A1 Oral administration of epothilones
10/16/2003WO2003084520A2 Pharmaceutical preparation containing oxycodone and naloxone
10/16/2003WO2003084519A2 Aerosol formulation for inhalation comprising a tiotropium salt
10/16/2003WO2003084518A2 Oral suspension of active principle microcapsules
10/16/2003WO2003084517A2 Oral suspension of amoxicillin capsules
10/16/2003WO2003084516A1 Polysaccharide capsules and methods of preparation
10/16/2003WO2003084511A1 Palatable chewable tablet
10/16/2003WO2003084509A1 Powder formulations suitable for inhalation
10/16/2003WO2003084508A1 Delivery of a substance to a pre-determined site
10/16/2003WO2003084506A1 Aqueous formulations of (2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluorobutane-1-sulfonate
10/16/2003WO2003084504A2 Matrix for sustained, invariant and independent release of active compounds
10/16/2003WO2003084503A2 P38 kinase inhibitors for treating mucus hypersecretion_
10/16/2003WO2003084498A1 Hydrogel adhesives for use on hair or fiber-populated surfaces
10/16/2003WO2003084481A2 Biological affinity based delivery systems
10/16/2003WO2003084470A2 Compositions and methods for targeted biological delivery of molecular carriers
10/16/2003WO2003084469A2 Tissue-specific endothelial membrane proteins
1 ... 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 ... 1712